Invest in Filana Therapeutics, Inc on Stash
Filana Therapeutics is a clinical-stage biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and potentially other indications. Simufilam is a proprietary, investigational oral small molecule believed to modulate activity of the filamin A (FLNA) protein, which regulates diverse aspects of neuronal development. Studies conducted in the lab of Dr. Angélique Bordey at Yale School of Medicine provide the foundation for developing simufilam as a therapy for TSC and other mTOR pathway disorders. In a mouse model of focal onset seizures due to TSC-related pathology, the Bordey lab showed that treating mice with simufilam, before or after seizure onset, reduced seizure frequency by 60% compared to vehicle-treated mice. More recently, a study in a TSC mouse model conducted with the TSC Alliance’s Preclinical Consortium showed that simufilam attenuated the progression of seizure activity in a dose-dependent manner, supporting planning a clinical study.
Ticker: FLNA
Filana Therapeutics, Inc
$1.61
-4.17%
$
FLNA Performance Breakdown
Share Price
$1.61
Today's change
1.26%
Year to date change (YTD)
-22.97%
Dividend yield
0.0
Last dividend paid
N/A
Last dividend pay date
N/A
About FLNA
Filana Therapeutics is a clinical-stage biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and potentially other indications. Simufilam is a proprietary, investigational oral small molecule believed to modulate activity of the filamin A (FLNA) protein, which regulates diverse aspects of neuronal development. Studies conducted in the lab of Dr. Angélique Bordey at Yale School of Medicine provide the foundation for developing simufilam as a therapy for TSC and other mTOR pathway disorders. In a mouse model of focal onset seizures due to TSC-related pathology, the Bordey lab showed that treating mice with simufilam, before or after seizure onset, reduced seizure frequency by 60% compared to vehicle-treated mice. More recently, a study in a TSC mouse model conducted with the TSC Alliance’s Preclinical Consortium showed that simufilam attenuated the progression of seizure activity in a dose-dependent manner, supporting planning a clinical study.
Filana Therapeutics, Inc Stock Ticker
FLNA
For more information
Invest in Filana Therapeutics, Inc on Stash
Filana Therapeutics is a clinical-stage biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and potentially other indications. Simufilam is a proprietary, investigational oral small molecule believed to modulate activity of the filamin A (FLNA) protein, which regulates diverse aspects of neuronal development. Studies conducted in the lab of Dr. Angélique Bordey at Yale School of Medicine provide the foundation for developing simufilam as a therapy for TSC and other mTOR pathway disorders. In a mouse model of focal onset seizures due to TSC-related pathology, the Bordey lab showed that treating mice with simufilam, before or after seizure onset, reduced seizure frequency by 60% compared to vehicle-treated mice. More recently, a study in a TSC mouse model conducted with the TSC Alliance’s Preclinical Consortium showed that simufilam attenuated the progression of seizure activity in a dose-dependent manner, supporting planning a clinical study.
Certain companies are volatile
Certain companies can be volatile, meaning the stock price fluctuates significantly. Don’t put all your eggs into one basket and remember to keep the Stash Way in mind when you invest.
Filana Therapeutics, Inc stock news
Why invest with Stash?
Fractional shares
Thousands of stocks and ETFs. No investing minimums.
Unlimited trades
Plus no add-on trading commission fees.†
Diversification analysis
Custom investment recommendations can help you diversify.
Automatic investing
Dividend reinvestment,8 recurring investments, and more.
The Stock-Back® Card
We’ll give you matching stock in companies you shop at.1
Learn how to invest
Get professional advice and education at every step.
How to buy Filana Therapeutics, Inc stock on Stash
Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive.
Stash offers two subscription plans: Stash Growth and Stash+.
Once your market order of Filana Therapeutics, Inc stock is complete, you'll officially be a shareholder of Filana Therapeutics, Inc!
Invest in Filana Therapeutics, Inc on Stash
Filana Therapeutics is a clinical-stage biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and potentially other indications. Simufilam is a proprietary, investigational oral small molecule believed to modulate activity of the filamin A (FLNA) protein, which regulates diverse aspects of neuronal development. Studies conducted in the lab of Dr. Angélique Bordey at Yale School of Medicine provide the foundation for developing simufilam as a therapy for TSC and other mTOR pathway disorders. In a mouse model of focal onset seizures due to TSC-related pathology, the Bordey lab showed that treating mice with simufilam, before or after seizure onset, reduced seizure frequency by 60% compared to vehicle-treated mice. More recently, a study in a TSC mouse model conducted with the TSC Alliance’s Preclinical Consortium showed that simufilam attenuated the progression of seizure activity in a dose-dependent manner, supporting planning a clinical study.
